A	B	C
1	Main
2		Brand Name	Relovair (fka Beyond Advair, HORIZON), fka 444, 698
3		Generic Name	fluticasone furoate, vilanterol trifenatate
4		Mechanism	Inhaled corticosteroid and LABA combination
5			Note that fluticasone propionate is the steroid in Advair and Flonase. Fluticasone furoate is a different steroid, which is Veramyst.
6		Administration	Once-daily inhalation
7		Economics	THRX
8		Device	Single step activation inhaler
9		Clinical Trials
10			Phase III Relovair 100/25mcg against fluticasone furoate 100mcg in uncontrolled asthma patients
11			Time to first severe asthma exacerbation is the primary endpoint.
12
13			Phase III Relovair versus Advair 24-week study
14
15			Phase III fluticasone furoate versus fluticasone propionate versus placebo
16
17			Phase III COPD n=1560
18			Three doses of FF combined with 25mcg of 444 versus 444 monotherapy dosed once daily.
19
20			961081 Phase IIB COPD - Initiated 12/21/10
21			n=425 100mcg, 400mcg, 800mcg QD and 100mcg, 200mg and 400mcg BID versus 50mcg salmterol versus placebo in DISKUS.
22
23			642444 - Phase 2B started 12/07 - "HORIZON" '444 is the LABA n=600 asthma
24			New inhaler used.
25
26			685698 - Phase 2B started 12/07 - "HORIZON" 698 is the steroid n=1800
27			New inhaler used.
28			Showed dose curve of no response at 25mcg with toxicity of urinary cortisol reduction at 800mcg.
29
30			685698 - Phase II in Asthma, started 10/08 n=750
31			qd and bid tested.
32
33			705/244 Phase II COPD study
34
35			698/444 combination study.
36
37			698/444 Phase III study
38
39			159797 - qd beta2 agonist - asthma & COPD in combination with a glucocorticoid agonist
40			159802 - LABA beta2
41			799943, 685698 - glucocorticoid agonist
42			698 efficacious in phase 2
43			233705/642444
44			573719/vilanterol - Combiation LAMA/LABA in Phase III
45			961081 - muscarinic antagonist and a beta2receptor agonist.